OncoDNA announces publication of peer-reviewed study in Oncotarget assessing the utility of its uniq

(Rapamycin Press) OncoDNA treatment recommendation followed in 60% of cases. 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA. 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival >12 months, compared to a typical average of no more than six months.